Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Postprandial lipemia is highly prevalent in type 2 diabetes subjects even with normal fasting
triglyceride values. Humans are mostly in a postprandial rather than in a fasting state and
therefore non-fasting triglyceride values reflect more accurately the continuous exposure of
arterial wall to the substantial cholesterol load from remnant particles. Evolocumab lowers
blood LDL-cholesterol. This study evaluates the effect of evolocumab on postprandial lipid
metabolism in type 2 diabetes. All participants in this study receive evolocumab treatment.